Pfizer, a top pharma company will soon shift certain U.S. promotional responsibilities for the blockbuster anti-inflammatory drug Enbrel to its marketing partner, Amgen, as the drug makers prepare to wind down a longstanding North American partnership.
Pfizer and Amgen, both top pharma companies have agreed to consolidate all U.S. field sales activities under Amgen, effective July 23, spokeswomen for both companies confirmed Wednesday. The changes are specific to the U.S. and Puerto Rico, and don't affect Canada.
The top pharma companies said the move will ensure continuity in customer service as they prepare for ...
Read the full article at Wall Street Journal (link no longer working)
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity